Current concept and epidemiology of systemic vasculitides

Allergology International

Volumn 63, Issue 4, 2014, Pages 505-513

  Katsuyama, Takayuki ^a   Sada, Ken Ei ^a   Makino, Hirofumi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Antineutrophil cytoplasmic antibody associated vasculitis; Chapel Hill Consensus Conference nomenclature of systemic vasculitides; Epidemiology; Large vessel vasculitis; Polyarteritis nodosa

Indexed keywords

ANCA ASSOCIATED VASCULITIS; AORTA ARCH SYNDROME; ASIA; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DISEASE CLASSIFICATION; ETHNIC DIFFERENCE; EUROPE; GIANT CELL ARTERITIS; HUMAN; INTERSTITIAL LUNG DISEASE; MICROSCOPIC POLYANGIITIS; MORBIDITY; POLYARTERITIS NODOSA; PREVALENCE; PRIORITY JOURNAL; REVIEW; SYSTEMIC VASCULITIS; UNITED STATES; WEGENER GRANULOMATOSIS;

HUMANS; SYSTEMIC VASCULITIS;

EID: 84924761869     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.14-RAI-0778     Document Type: Review

References (93)

1. Zeek PM. Periarteritis nodosa; a critical review. Am J Clin Pathol 1952;22:777-90.
2. Zeek PM. Periarteritis nodosa and other forms of necrotizing angiitis. N Engl J Med 1953;248:764-72.
3. Godman GC, Churg J. Wegener’s granulomatosis: pathology and review of the literature. AMA Arch Pathol 1954; 58:533-53.
4. De RR, McDonald TJ, Harrison EG Jr, Coles DT. Wegener’s granulomatosis. Anatomic correlates, a proposed classification. Mayo Clin Proc 1976;51:777-81.
5. Fries JF, Hunder GG, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum 1990;33:1135-6.
6. Hunder GG, Bloch DA, Michel BA et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:1122-8.
7. Arend WP, Michel BA, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990;33:1129-34.
8. Leavitt RY, Fauci AS, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 1990;33: 1101-7.
9. Masi AT, Hunder GG, Lie JT et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990;33:1094-100.
10. Lightfoot RW Jr, Michel BA, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 1990;33: 1088-93.
11. Mills JA, Michel BA, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of Henoch-Schonlein purpura. Arthritis Rheum 1990;33: 1114-21.
12. Calabrese LH, Michel BA, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis. Arthritis Rheum 1990; 33:1108-13.
13. Rao JK, Allen NB, Pincus T. Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis. Ann Intern Med 1998;129: 345-52.
14. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92.
15. Sorensen SF, Slot O, Tvede N, Petersen J. A prospective study of vasculitis patients collected in a five year period: evaluation of the Chapel Hill nomenclature. Ann Rheum Dis 2000;59:478-82.
16. Lane SE, Watts RA, Barker TH, Scott DG. Evaluation of the Sorensen diagnostic criteria in the classification of systemic vasculitis. Rheumatology (Oxford) 2002;41:1138-41.
17. Watts R, Lane S, Hanslik T et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007; 66:222-7.
18. Liu LJ, Chen M, Yu F, Zhao MH, Wang HY. Evaluation of a new algorithm in classification of systemic vasculitis. Rheumatology (Oxford) 2008;47:708-12.
19. Kamali S, Artim-Esen B, Erer B et al. Re-evaluation of 129 patients with systemic necrotizing vasculitides by using classification algorithm according to consensus methodology. Clin Rheumatol 2012;31:325-8.
20. Jennette JC, Falk RJ, Bacon PA et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65:1-11.
21. Guillevin L, Lhote F, Amouroux J, Gherardi R, Callard P, Casassus P. Antineutrophil cytoplasmic antibodies, abnormal angiograms and pathological findings in polyarteritis nodosa and Churg-Strauss syndrome: indications for the classification of vasculitides of the polyarteritis Nodosa Group. Br J Rheumatol 1996;35:958-64.
22. Lionaki S, Blyth ER, Hogan SL et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 2012;64:3452-62.
23. Lyons PA, Rayner TF, Trivedi S et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012;367:214-23.
24. Hoffman GS, Calabrese LH. Vasculitis: determinants of disease patterns. Nat Rev Rheumatol 2014;10:454-62.
25. Yamada I, Nakagawa T, Himeno Y, Numano F, Shibuya H. Takayasu arteritis: evaluation of the thoracic aorta with CT angiography. Radiology 1998;209:103-9.
26. Yamada I, Nakagawa T, Himeno Y, Kobayashi Y, Numano F, Shibuya H. Takayasu arteritis: diagnosis with breathhold contrast-enhanced three-dimensional MR angiography. J Magn Reson Imaging 2000;11:481-7.
27. Karahaliou M, Vaiopoulos G, Papaspyrou S, Kanakis MA, Revenas K, Sfikakis PP. Colour duplex sonography of temporal arteries before decision for biopsy: a prospective study in 55 patients with suspected giant cell arteritis. Arthritis Res Ther 2006;8:R116.
28. Sinha D, Mondal S, Nag A, Ghosh A. Development of a colour Doppler ultrasound scoring system in patients of Takayasu’s arteritis and its correlation with clinical activity score (ITAS 2010). Rheumatology (Oxford) 2013;52: 2196-202.
29. Muto G, Yamashita H, Takahashi Y et al. Large vessel vasculitis in elderly patients: early diagnosis and steroidresponse evaluation with FDG-PET[1]CT and contrastenhanced CT. Rheumatol Int. Epub 2014 Mar 19.
30. Prieto-Gonzalez S, Depetris M, Garcia-Martinez A et al. Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsyproven giant cell arteritis: a prospective, case-control study. Ann Rheum Dis 2014;73:1388-92.
31. Craven A, Robson J, Ponte C et al. ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS). Clin Exp Nephrol 2013;17:619-21.
32. Luqmani RA, Suppiah R, Grayson PC, Merkel PA, Watts R. Nomenclature and classification of vasculitis - update on the ACR[1]EULAR diagnosis and classification of vascu litis study (DCVAS). Clin Exp Immunol 2011;164 (Suppl 1):11-3.
33. Haugeberg G, Bie R, Bendvold A, Larsen AS, Johnsen V. Primary vasculitis in a Norwegian community hospital: a retrospective study. Clin Rheumatol 1998;17:364-8.
34. Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, Gross WL. Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum 2005;53:93-9.
35. Gonzalez-Gay MA, Garcia-Porrua C, Guerrero J, Rodriguez- Ledo P, Llorca J. The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions. Arthritis Rheum 2003;49:388-93.
36. Herlyn K, Buckert F, Gross WL, Reinhold-Keller E. Doubled prevalence rates of ANCA-associated vasculitides and giant cell arteritis between 1994 and 2006 in northern Germany. Rheumatology (Oxford) 2014;53:882-9.
37. Mohammad AJ, Jacobsson LT, Westman KW, Sturfelt G, Segelmark M. Incidence and survival rates in Wegener’s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology (Oxford) 2009;48:1560-5.
38. Fujimoto S, Uezono S, Hisanaga S et al. Incidence of ANCA-associated primary renal vasculitis in the Miyazaki Prefecture: the first population-based, retrospective, epidemiologic survey in Japan. Clin J Am Soc Nephrol 2006; 1:1016-22.
39. Fujimoto S, Watts RA, Kobayashi S et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibodyassociated vasculitis between Japan and the U.K. Rheumatology (Oxford) 2011;50:1916-20.
40. Oh JS, Lee CK, Kim YG, Nah SS, Moon HB, Yoo B. Clinical features and outcomes of microscopic polyangiitis in Korea. J Korean Med Sci 2009;24:269-74.
41. Chen M, Yu F, Zhang Y, Zhao MH. Clinical [corrected] and pathological characteristics of Chinese patients with antineutrophil cytoplasmic autoantibody associated systemic vasculitides: a study of 426 patients from a single centre. Postgrad Med J 2005;81:723-7.
42. Sada KE, Yamamura M, Harigai M et al. Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res Ther 2014;16:R101.
43. Wu CS, Hsieh CJ, Peng YS, Chang TH, Wu ZY. Antineutrophil cytoplasmic antibody-associated vasculitis in Taiwan: A hospital-based study with reference to the population-based National Health Insurance database. J Microbiol Immunol Infect 2014. DOI: 10.1016[1]j.jmii.2013.12.006.
44. Sugiyama K, Sada KE, Kurosawa M, Wada J, Makino H. Current status of the treatment of microscopic polyangiitis and granulomatosis with polyangiitis in Japan. Clin Exp Nephrol 2013;17:51-8.
45. Arulkumaran N, Periselneris N, Gaskin G et al. Interstitial lung disease and ANCA-associated vasculitis: a retrospective observational cohort study. Rheumatology (Oxford) 2011;50:2035-43.
46. Bhanji A, Karim M. Pulmonary fibrosis-an uncommon manifestation of anti-myeloperoxidase-positive systemic vasculitis? NDT plus 2010;3:351-3.
47. Foulon G, Delaval P, Valeyre D et al. ANCA-associated lung fibrosis: analysis of 17 patients. Respir Med 2008; 102:1392-8.
48. Hervier B, Pagnoux C, Agard C et al. Pulmonary fibrosis associated with ANCA-positive vasculitides. Retrospective study of 12 cases and review of the literature. Ann Rheum Dis 2009;68:404-7.
49. Luqmani RA, Bacon PA, Moots RJ et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994;87:671-8.
50. Mukhtyar C, Lee R, Brown D et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009;68:1827-32.
51. Itabashi M, Takei T, Morito T et al. Estimation of BVAS in patients with microscopic polyangiitis in Japan. Clin Rheumatol 2011;30:1499-505.
52. Sreih AG, Mandhadi R, Aldaghlawi F et al. ANCAassociated vasculitis in Hispanic Americans: an unrecognized severity. Clin Rheumatol. Epub 2014 Apr 22.
53. Ugarte-Gil MF, Espinoza LR. Genetics of ANCAassociated vasculitides. Curr Rheumatol Rep 2014;16:428.
54. Mahr A, Guillevin L, Poissonnet M, Ayme S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener’s granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capturerecapture estimate. Arthritis Rheum 2004;51:92-9.
55. Mohammad AJ, Jacobsson LT, Mahr AD, Sturfelt G, Segelmark M. Prevalence of Wegener’s granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg- Strauss syndrome within a defined population in southern Sweden. Rheumatology (Oxford) 2007;46:1329-37.
56. Pagnoux C, Seror R, Henegar C et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum 2010;62:616-26.
57. Navon Elkan P, Pierce SB, Segel R et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med 2014;370:921-31.
58. Numano F. The story of Takayasu arteritis. Rheumatology (Oxford) 2002;41:103-6.
59. Numano F, Okawara M, Inomata H, Kobayashi Y. Takayasu’s arteritis. Lancet 2000;356:1023-5.
60. Dreyer L, Faurschou M, Baslund B. A population-based study of Takayasu’s arteritis in eastern Denmark. Clin Exp Rheumatol 2011;29 (Suppl 64):S40-2.
61. Hall S, Barr W, Lie JT, Stanson AW, Kazmier FJ, Hunder GG. Takayasu arteritis. A study of 32 North American patients. Medicine (Baltimore) 1985;64:89-99.
62. Waern AU, Andersson P, Hemmingsson A. Takayasu’s arteritis: a hospital-region based study on occurrence, treatment and prognosis. Angiology 1983;34:311-20.
63. Watts R, Al-Taiar A, Mooney J, Scott D, Macgregor A. The epidemiology of Takayasu arteritis in the UK. Rheumatology (Oxford) 2009;48:1008-11.
64. JCS Joint Working Group. Guideline for management of vasculitis syndrome (JCS 2008). Japanese Circulation Society. Circ J 2011;75:474-503.
65. Numano F. Differences in clinical presentation and outcome in different countries for Takayasu’s arteritis. Curr Opin Rheumatol 1997;9:12-5.
66. Isobe M. Takayasu arteritis revisited: current diagnosis and treatment. Int J Cardiol 2013;168:3-10.
67. Moriwaki R, Numano F. Takayasu arteritis: follow-up studies for 20 years. Heart Vessels Suppl 1992;7:138-45.
68. Lee SW, Kwon OJ, Park MC, Oh HB, Park YB, Lee SK. HLA alleles in Korean patients with Takayasu arteritis. Clin Exp Rheumatol 2007;25 (Suppl 44):S18-22.
69. Mehra NK, Jaini R, Balamurugan A et al. Immunogenetic analysis of Takayasu arteritis in Indian patients. Int J Cardiol 1998;66 (Suppl 1):S127-32; discussion S33.
70. Charoenwongse P, Kangwanshiratada O, Boonnam R, Hoomsindhu U. The association between the HLA antigens and Takayasu’s arteritis in Thai patients. Int J Cardiol 1998;66 (Suppl 1):S117-20.
71. Sahin Z, Bicakcigil M, Aksu K et al. Takayasu’s arteritis is associated with HLA-B*52, but not with HLA-B*51, in Turkey. Arthritis Res Ther 2012;14:R27.
72. Takamura C, Ohhigashi H, Ebana Y, Isobe M. New human leukocyte antigen risk allele in Japanese patients with Takayasu arteritis. Circ J 2012;76:1697-702.
73. Saruhan-Direskeneli G, Hughes T, Aksu K et al. Identification of multiple genetic susceptibility loci in Takayasu arteritis. Am J HumGenet 2013;93:298-305.
74. Richards BL, March L, Gabriel SE. Epidemiology of largevessel vasculidities. Best Pract Res Clin Rheumatol 2010; 24:871-83.
75. Haugeberg G, Paulsen PQ, Bie RB. Temporal arteritis in Vest Agder County in southern Norway: incidence and clinical findings. J Rheumatol 2000;27:2624-7.
76. Petursdottir V, Johansson H, Nordborg E, Nordborg C. The epidemiology of biopsy-positive giant cell arteritis: special reference to cyclic fluctuations. Rheumatology (Oxford) 1999;38:1208-12.
77. Franzen P, Sutinen S, von Knorring J. Giant cell arteritis and polymyalgia rheumatica in a region of Finland: an epidemiologic, clinical and pathologic study, 1984-1988. J Rheumatol 1992;19:273-6.
78. Baldursson O, Steinsson K, Bjornsson J, Lie JT. Giant cell arteritis in Iceland. An epidemiologic and histopathologic analysis. Arthritis Rheum 1994;37:1007-12.
79. Elling P, Olsson AT, Elling H. Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection. J Rheumatol 1996;23:112-9.
80. Salvarani C, Macchioni P, Zizzi F et al. Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. Arthritis Rheum 1991; 34:351-6.
81. Gonzalez-Gay MA, Miranda-Filloy JA, Lopez-Diaz MJ et al. Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study. Medicine (Baltimore) 2007;86:61-8.
82. Pereira LS, Yoon MK, Hwang TN et al. Giant cell arteritis in Asians: a comparative study. Br J Ophthalmol 2011;95: 214-6.
83. Kobayashi S, Yano T, Matsumoto Y et al. Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: the first government-supported nationwide survey. Arthritis Rheum 2003;49:594-8.
84. Kobayashi S, Fujimoto S. Epidemiology of vasculitides: differences between Japan, Europe and North America. Clin Exp Nephrol 2013;17:611-4.
85. Weyand CM, Hicok KC, Hunder GG, Goronzy JJ. The HLA-DRB1 locus as a genetic component in giant cell arteritis. Mapping of a disease-linked sequence motif to the antigen binding site of the HLA-DR molecule. J Clin Invest 1992;90:2355-61.
86. Moriwaki R, Noda M, Yajima M, Sharma BK, Numano F. Clinical manifestations of Takayasu arteritis in India and Japan-new classification of angiographic findings. Angiology 1997;48:369-79.
87. Salvarani C, Crowson CS, O’Fallon WM, Hunder GG, Gabriel SE. Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. Arthritis Rheum 2004;51:264-8.
88. Jayne D, Rasmussen N, Andrassy K et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44.
89. de Groot K, Harper L, Jayne DR et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009;150:670-80.
90. De Groot K, Rasmussen N, Bacon PA et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461-9.
91. Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221-32.
92. Jones RB, Tervaert JW, Hauser T et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010;363:211-20.
93. Jayne DR, Chapel H, Adu D et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 2000;93:433-9.